NEW YORK (GenomeWeb) – Second Genome today announced it has entered into a research alliance with the Alimentary Pharmabiotic Centre (APC) Microbiome Institute at University College Cork (UCC) in Ireland.

The partners said they will develop therapies to prevent and treat inflammatory bowel disease (IBD) based on the role of the microbiome. To do so, they will analyze data from patients to find new opportunities for treatment. Second Genome has developed a drug discovery platform that integrates microbiome and host biology, the firm said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.